Accutane (Isotretinoin) Regret, Stopping, and Restarting: What Real Patients and Clinical Data Show

What the evidence shows about stopping

Published studies count relapse, retreatment and repeat courses, not how patients feel about the decision to stop. The Accutane label states that a single 15 to 20 week course has been shown to result in complete and prolonged remission in many patients [3]. The cohort data below show that acne does return for a sizable share of people.

How often acne comes back after a course

The largest dataset is a nested case-control study built from Quebec administrative health databases. It assembled a cohort of 17,351 first-time isotretinoin users between 1984 and 2003. Of those, 7,100 (41%) later filled a prescription for an acne medication, which the authors counted as relapse, and 4,443 (26%) went on to a second isotretinoin course [1].

Relapse was statistically associated with being male, being under 16 at treatment, living in an urban area, a cumulative dose above 2,450 mg, and a treatment course longer than 121 days [1]. These are associations from prescription records, not proof that any one factor causes relapse.

Newer data come from a single-centre, single-blind randomized trial with blinded outcome assessment in moderate-to-severe cystic acne, comparing cumulative doses of 120 and 150 mg/kg. Twelve months after treatment stopped, relapse was 26.7% in the 120 mg/kg group and 32.3% in the 150 mg/kg group (p = 0.619) [4].

Where the 120 to 150 mg/kg figure comes from

The Absorica and Absorica LD label gives daily dosing, not a total. It specifies 0.5 to 1 mg/kg/day of Absorica in two divided doses for 15 to 20 weeks, or 0.4 to 0.8 mg/kg/day of Absorica LD, with up to 2 mg/kg/day of Absorica (1.6 mg/kg/day of Absorica LD) for adults with very severe disease such as scarring or trunk involvement [2]. Once-daily dosing is not recommended [2]. Neither the Absorica label nor the older-format Accutane label states a cumulative mg/kg target [2][3].

The 120 to 150 mg/kg range comes from the medical literature. In a survey of 1,000 patients treated by 12 dermatologists with a special interest in acne, most of the physicians aimed for a cumulative dose above 100 to 120 mg/kg [6]. The 2026 randomized trial of 120 versus 150 mg/kg describes 120 mg/kg as the standard dose [4].

Does a lower daily dose mean more retreatment?

The classic dose-response trial enrolled 150 patients with treatment-resistant nodulocystic acne and randomized them double-blind to 0.1, 0.5 or 1.0 mg/kg/day in equal groups. All three doses produced a highly significant clinical response, with no significant difference in response between them. However, 42% of the patients on 0.1 mg/kg/day required retreatment, and the authors concluded that higher doses were indicated [5].

Does pushing the total dose to 150 mg/kg help?

In the 2026 trial, both cumulative-dose groups improved comparably in total lesion count and acne severity grade from baseline to the end of treatment, with no significant difference between groups (all p > 0.20). Scarring did not worsen during treatment, and adverse events were mild and comparable between arms [4].

The authors concluded that raising the dose to 150 mg/kg provides no benefit, that extended therapy does not reduce relapse, and that 120 mg/kg is optimal; they also noted that persistent acne required longer treatment [4]. The trial was single-centre with retrospective registration, which limits how far the result generalizes [4].

When the labels allow a second course

The Absorica label says a second course is not recommended before a 2-month waiting period, because acne may continue to improve after a 15 to 20 week course [2]. The Accutane label puts the same idea at no earlier than 8 weeks after the first course is completed, and notes that the optimal interval before retreatment has not been defined for patients who have not completed skeletal growth [3].

Both labels also describe a planned early stop. If the total nodule count has fallen by more than 70% before 15 to 20 weeks, the drug may be discontinued; a second course can follow after 2 months or more off treatment if severe nodular acne persists or recurs [2][3].

The Accutane label states that long-term use, even at low doses, has not been studied and is not recommended, and that the effect of long-term use on bone loss is unknown [3].

What second and third courses actually achieve

A nine-year prospective series followed 188 acne patients (113 male, 75 female; mean age 25) treated with 0.5 to 1 mg/kg, with treatment continued until 2 months after total healing and then regular review. At the end, 111 patients had stable long-term remission after a single course (average follow-up 27 months), 54 had stable remission after two or three courses (average follow-up 16 months), and 23 had only partial remission [7].

The partial-response group differed from the others: it contained a greater proportion of patients with microcystic acne (p < 0.05) and more women with endocrinological problems (p < 0.001) [7].

Side effects and label stop points

A systematic review of 11 randomized trials totaling 760 patients found that isotretinoin reduced acne lesion counts by a clinically relevant amount and always by more than control. Adverse events were twice as frequent with isotretinoin (751 events) as with control (388), and more than half of all adverse events were dermatological and dryness-related [8]. Twelve patients withdrew from trials because of Stevens-Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches and depressed mood [8].

The Absorica label notes that cheilitis and hypertriglyceridemia are dose related [2], and the Accutane label states that during treatment the dose may be adjusted according to the response of the disease and the appearance of clinical side effects, some of which may be dose related [3].

Some situations are label stop points rather than dose-adjustment points. The Absorica label lists depression, mood disturbance, psychosis or aggression as reasons to stop the drug immediately and seek further evaluation [2]. It says to discontinue for symptoms of pancreatitis, for serious skin reactions, and for hearing impairment, with referral to specialized care for the last of these [2]. It also says to discontinue for abdominal pain, rectal bleeding or severe diarrhea, and to discontinue and refer for an ophthalmological exam if visual symptoms occur [2]. If hypertriglyceridemia cannot be controlled, the label says to stop [2].

iPLEDGE again for a repeat course

Every patient is enrolled in the iPLEDGE REMS, not only patients who can get pregnant. Patients who cannot get pregnant must not share the drug or donate blood [2]. Patients who can get pregnant must have a screening pregnancy test in a medical setting and a confirmatory test in a medical setting at least 30 days later and after at least 30 days of using the chosen pregnancy prevention, then a pregnancy test within 7 days before each prescription, with testing also required after treatment [2]. Pharmacies dispense a maximum 30-day supply with a Medication Guide and no refills [2][3].

FDA approved modifications to the iPLEDGE REMS on 2026-02-09, including the option for prescriber-approved home pregnancy tests during and after treatment, while pre-treatment tests stay in a medical setting. The planned implementation date is 2026-11-15, delayed from 2026-08-08 [9]. The Absorica label effective 2026-08-19 already contains the home-test language [2].